Regulation of multidrug resistance in Lactococcus lactis by Agustiandari, Herfita
  
 University of Groningen
Regulation of multidrug resistance in Lactococcus lactis
Agustiandari, Herfita
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2009
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Agustiandari, H. (2009). Regulation of multidrug resistance in Lactococcus lactis. Groningen: s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the














THE RISE OF THE SUPERBUGS 
 
Just about all organisms maintain close physical contact with other organisms in a 
changeable and dynamic ecosystem. Networking is important to cope with sudden 
environmental changes and it is beneficial for survival. Changing conditions and 
competition amongst organisms for essential nutrients, together with humans’ 
interference in the global biosphere have lead to rapid evolutionary changes in all 
organisms involved. The first introduction of pesticides and antibiotics during the 
industrialization era in 1940’s significantly increased the quality of humans’ life as 
it provided protection against pests and infections caused by pathogenic bacteria 
(121). However, due to the extensive use of antibiotics and other toxic compounds, 
bacteria quickly developed numerous ways to gain resistance against these 
molecules. The ability of bacteria to be resistant to several chemically unrelated 
drugs is termed the multidrug resistance (MDR) phenomenon. Bacterial MDR was 
thought to arise via natural selection involving spontaneous mutation(s) in the 
genome to execute novel activities against a range of antibiotics. This resistant trait 
is generally passed on to the next generation and quickly leads to a fully resistant 
colony. It is important to note that bacteria did not evolve a specific response 
towards the presence of antibiotics. Rather, they became resistant via the 
mobilization and/or modification of pre-existing defense mechanisms that allow 
them to cope with the unfavorable environmental conditions (157).  
  One specific example of drug resistance is the re-emergence of the 
multidrug resistant tuberculosis bacterial strain (MDR-TB) which emphasizes the 
need for a new strategy and control of infectious disease since treatment with 
conventional drugs such as rifampicin and isoniazid have failed frequently (63). 
The first report on MDR-TB from 2005 showed that this organism is not only 
resistant to the previously used drugs but also to three out of six classes of second 
line antitubercular drugs like aminoglycosides, polypeptides, fluoroquinolones, 
thioamides, cycloserine and para-aminosalycilic (63). This new strain is also 
known as the extensively drug resistance tuberculosis (XDR-TB) that has emerged 
due to the improper use of antibiotics during treatments of tuberculosis (60). 
Another concerning example is the methicilin-resistant Staphylococcus aureus 
(MRSA), a major cause of nosocomial infections that can be acquired in hospitals. 
This organism readily takes up new plasmids, transposons, and its genome easily 
undergoes mutations. Its resistance to the blockbuster antibiotic vancomycin has 
lead to the emergence of a new strain known as VRSA (vancomycin resistant S. 
aureus) (1). 
  Molecular studies on multidrug resistance intensified after the discovery of 





P-gp survived the cytotoxic effects of anti cancer drugs during therapy, and became 
cross resistant to a wide range of drugs from different classes (157). Shortly after 
the discovery of P-gp, bacterial resistance to antibiotics became apparent (75,105) 
as well as for instance the emergence of resistant insects to pesticides (12,41). 
Multidrug resistant bacteria were first observed in 1960s (176), followed by the 
discovery of cross resistant tumors and cell lines which occurred after the 
introduction of combined chemotherapy (19,67). P-gp is a transport protein that 
expels drugs from the cell thus, protects the cells against the adverse effects of 
these drugs.  
 
 
MULTIDRUG RESISTANCE IN BACTERIA 
 
Several mechanisms exist to gain resistance to toxic compounds. They are based on 
drug degradation via enzymatic reactions, an alteration of the drug target, the 
prevention of drug entry, and finally the active drug expulsions from the cell. For 
instance, some bacteria produce β-lactamases that catalyze the hydrolysis of the β-
lactam ring of penicillin (162) while chloroamphenicol transferase modifies 
aminoglycosides into inactive entities (11). Drug target alteration prevents or 
reduces the binding of the drug. For instance, some amino acid mutations in 
penicillin binding proteins (PBPs) prevent the irreversible binding of penicillin 
which subsequently renders peptidoglycan biosynthesis penicillin-insensitive 
(162). In tetracycline resistant bacteria, the ribosomes often undergo a covalent 
modification that prevents the binding of tetracycline (160). However, these 
mechanisms are specific only to certain classes of antibiotics and usually do not 
results in multidrug resistance. Bacteria contain a cytoplasmic membrane that 
function as a barrier that separates the inner and the outer part of the cell. This 
barrier also prevents the rapid entry of small molecules like drug(s). Gram-negative 
bacteria contain an additional outer membrane that consists of phospholipids and 
lipopolysaccharides (LPS) which exhibits a reduced permeability towards 
lipophilic drugs. Gram-positive bacteria have no outer membrane but instead a 
thick peptidoglycan layer that allows diffusion of small molecules (108). 
Mycobacteria on the other hand, contain a thick extracellular layer of mycolic acids 
that is highly impermeable for drugs. Both Gram-negative bacteria and 
mycobacteria can decrease their membrane permeability via the loss of porins 
(107). However, these barriers do not counteract the toxicity effect of the drugs 
once they enter the cells. Therefore, cells need another line of defense and one of 
the most common mechanisms is the active drug extrusion from the cell by 





energy dependent phenomenon and a growing number of membrane proteins have 
been described to function as multidrug resistance efflux proteins. The active 
extrusion of drugs appears to be the main mechanism of MDR and SDR (specific 
drug resistance) in bacteria (132). 
 
 
MULTIDRUG RESISTANCE TRANSPORTERS IN BACTERIA  
 
Tetracycline resistance in both Gram-positive and -negative bacteria is due to the 
expression of transporters that mediate tetracycline efflux (28). These proteins 
belong to a large family of MDR transporters that are equipped with a broad 
substrate specificity of many chemically unrelated compounds (123,132,141). 
Based on their bioenergetic mechanisms and structural differences, bacterial MDR 
transporters can be divided into two major classes, i.e., primary and secondary 
transporters. Some bacteria mostly rely on the primary transporters for drug 
resistance, whereas others utilize the secondary transporters (125,126). Primary 
MDR transporters belong to the ABC superfamily and use the free energy derived 
from ATP hydrolysis to extrude toxic compounds from the cell (55). ABC 
transporters involved not only in drug export but also in a variety of other cellular 
activities such as peptide export, uptake of nutrients, and also in transport-unrelated 
functions such as DNA repair, translation, and regulation in gene expression 
(24,31,55). The proteins that are involved in the transport unrelated functions 
utilize the universally conserved ATP-binding cassette for their catalytic activities 
and lack the membrane domain. ABC transporters are membrane proteins with a 
typical organization, i.e., two nucleotide binding domains (NBD) where ATP 
hydrolysis take place, and two transmembrane domains (TMD) responsible for 
substrates recognition and transport (55). Each TMD consists of six membrane 
spanning α-helical domains with a low amino acid sequence identity among the 
group of ABC transporters. The two TMDs may exist as a single fused polypeptide 
chain that associates with a heterodimeric, homodimeric or even two fused NBDs. 
The MDR transporters are usually single polypeptides that each comprise of two 
TMDs and NBDs. Some MDR transports are homo- or heterdimeric proteins that 
built from subunits consisting of a TMD fused to the NBD. The secondary 
multidrug transporter mediate drugs extrusion in a coupled exchange with protons 
(or sodium ions) also known as drug/H+ or drug/Na+ antiporters (132). Secondary 
transporters form the largest group of known extrusion systems in bacteria 
comprising of four subdivisions, i.e., the major facilitator superfamily (MFS), the 
small multidrug resistance family (SMR), the resistance-nodulation-cell division 





These MDR transporters share little homology amongst each other but they may 




























Figure 1 Distribution of MDR pumps in Gram positive and negative bacteria. Primary 
transporters utilize the energy derived from ATP hydrolysis to secrete drugs out of the cells. They 
belong to the ATP-Binding Cassette (ABC) superfamily and function either as a homo- or hetero 
dimeric transporters. To date, many of the ABC type transporters involved in MDR are mostly found 
in the Gram positive bacteria. Secondary transporters are driven by the proton motive force (PMF), 
and catalyse drug export by H+/Na+ antiporter: Transporters of the Major Facilitator Superfamily 
(MFS) function as monomers, while trasnporters of the Small Multidrug Resistance family (SMR) 
function as either a homo or heterodimers. The Resistance-Nodulation-cell Division (RND) 
transporters consist of a tripartite system and functions as trimers. RND transporters are mainly found 
in the Gram negative bacteria and require accessories protein such as an outer membrane protein 
(OMP) and membrane fusion protein (MFP). Another member of the secondary transporters belongs 
to the MATE (Multi Antimicrobial Extrusion) family that use the sodium motive force.  
 
 
PHYSIOLOGICAL FUNCTIONS OF MULTIDRUG RESISTANCE IN 
BACTERIA 
 
The exact physiological function of most bacterial MDR transporters is unknown, 
but often they are involved in the defense mechanisms against specific class of 
chemical compounds. The MDR phenotype is often associated with an enhanced 
expression level of these transporters or by mutations in the structural gene. For 





increase efflux of spermidine in the medium (188). The blt gene is co transcribed 
with the bltD gene which encodes a spermidine acetyltransferase which catalyzes a 
key step in spermidine degradation. Reserpine, an antagonist of MDR transporters 
inhibits spermidine efflux by Blt (187) showing the close functional relationship of 
Blt with MDR transporters. The ability of some MDR transporters to recognize 
lipids or fluorescence lipid derivatives, and to transport detergent (133,185), bile 
salts (84,168), organic solvents (184), and ionophores (37,156), might indicate a 
natural functions in phospholipid transport or of lipid linked precursor of 
peptidoglycan (23,59,86,177,191). Various antibiotics that appear to be the 
substrates of the MexAB-OprM transporter of Pseudomonas aeruginosa are 
secondary metabolites that result from the aromatic amino acid biosynthesis 
pathway (129). For instance, the presence of iron in the medium significantly 
increased the expression of MexAB-OprM causing the efflux of peptide 
pyoverdine that is involved in iron uptake (130). This finding suggests a 
physiological role of MDR-like transporters in secondary metabolite excretion.  
 
 
REGULATION OF MULTIDRUG RESISTANCE IN BACTERIA 
 
Bacterial MDR can be either intrinsic or acquired. The basal expression of MDR 
pumps in the wild-type only suffices to provide a certain level of protection. At a 
higher drug concentration, resistance can be acquired via several mechanisms: (i) 
amplification and mutations of the MDR transporters causing changes in the 
expression level (106) or activity (70); (ii) mutations in the regulatory genes 
causing constitutive expression of the MDR transporters (2), and, (iii) resistance 
gene transfer among cells via transposons and plasmids (68) (For general review of 
mechanisms of bacterial resistance see refs (8,49)). Regulatory proteins respond to 
changes in the environment and trigger necessary cellular modifications at the 
transcriptional, translational or protein levels. Transcriptional regulators often 
comprise two-domains, i.e., the DNA binding domain and a ligand binding domain. 
Other regulatory mechanisms belong to the so-called two-component regulatory 
systems. Herein, the membrane-linked kinase acts as a sensor and in the presence 
of the inducer, the kinase will phosphorylate the DNA binding protein, which 
subsequently modulates the transcription of the gene(s) of interest by binding to the 
cognate promoter (135) (Table 1).  
  Although a lot of efforts have been made to understand the mechanisms of 
drug transporters in bacteria, the hydrophobic nature of these proteins make them 
intrinsically difficult to crystallize in order to obtain structural information. A few 





Sav1866 (32) however, the elucidation of the exact mechanism of action and the 
molecular basis of drug recognition and specificity remains a challenge. On the 
other hand, the structural and functional analysis of the regulatory pathways that 
govern the expression of these MDR transporters progresses rapidly. The 
expression level of many MDR transporters is closely controlled by inducers that 
are also substrates for the transporters. Many of the MDR transporters are subject 
for regulation by the transcriptional regulatory proteins. Gene regulation is crucial 
as an uncontrolled expression of the MDR transporter might be toxic to the cells. 
Transcriptional regulators are cytoplasmic proteins that can act as activators or 
repressors that influence transcription of target gene(s) at local or global level (46). 
Transcriptional regulators can also undergo autoregulation (2,56). A general 
mechanism for resistance development upon the exposure of cells to drugs or 
antibiotics is the immediate up-regulation of the low-expressed MDR transporters. 
For instance, the local transcriptional activator BmrR of Bacillus subtilis (3) and 
the transcriptional repressor QacR of Staphylococcus aureus (43) enhance the 
expression of the MDR transporters Bmr and QacA through the binding of 
chemically unrelated cationic drugs like tetraphenylphosphonium (TPP+) and 
Rhodamine 6G, respectively. The expression of E. coli RND transporter AcrAB is 
under the regulatory control by the global activators MarA, Rob, and SoxS (6). 
Derepression of mexAB-oprM operon in nalB-type mutant bearing mutation in 
mexR causes resistance phenotype to fluoroquinolones, chloroamphenicol, and β-
lactams antibiotics (131,142). The expression level of mexAB-oprM during the 
exponential growth phase is being control by the local transcriptional repressor 
MexR (36). Interestingly, in the early stationary phase of growth, a higher 
expression of mexAB-oprM is being modulated by the accumulation of quorum 
sensing autoinducer C4-HSL in the medium, and not by MexR (143). 
  The structural studies of transcriptional regulators of MDR transporters are 
of particular interest as it may provide an insight in the molecular basis of drug 
recognition. They often interact with the similar panel of substrates as recognized 
by the MDR transporter. A typical DNA binding domain of bacterial 
transcriptional regulators comprises an α-helix-turn-helix (HTH) motif that may be 
organized in different structural environments such as three-helix bundles and 
winged helix motifs (120). About 95% of all bacterial transcriptional factors use 
the HTH motif to bind to their target DNA (25,38,50,51,127,140). MDR related 
transcriptional regulators belong to one of the following families: AraC, MarR, 
MerR, and TetR. The distinction is based on the high level of similarity of the N-
terminus DNA binding domain that constitutes about one third of the polypeptide. 
Recent findings indicate some of the MDR-related transcriptional regulators belong 





Lactococcus lactis. PadR regulatory proteins are involved in the regulation of 
detoxification pathways in bacteria such as phenolic acid metabolism. The 
following section describes in detail mechanistic and functional aspects of MDR-
related transcriptional regulators  
 
QacR regulates the expression of the MDR transporter QacA/B in 
Staphylococcus aureus 
 
QacA and QacB are MDR transporters of S. aureus. These two nearly homologous 
genes belong to the MFS family. In a proton motive force (PMF)-dependent 
manner, they extrude a wide range of mono- or bivalent cationic lipophilic 
substrate from the cell. The identified substrate range encompasses of 12 different 
chemical groups (79,102,103,122) which mostly concern positively charged 
lipophilic compounds that are able to pass the cytoplasmic membrane, and 
accumulate in response to the transmembrane electrical potential, Δψ (negative 
inside). A gene located upstream of qacA termed qacR specifies a trans-acting 
transcriptional repressor of the qacAB genes. These genes are found on the multi 
resistance plasmids such as pSK1 present in clinical isolates (73,124,166,167). The 
QacR protein is a product of a divergently transcribed ORF that binds specifically 
to the promoter region of qacA thereby repressing its transcription (43). QacR 
belongs to the TetR/CamR family of transcriptional regulators that share a high 
degree of homology in their N-terminal DNA binding domains (139). In the 
absence of QacA substrates, QacR binds to a region of dyad symmetry (IR1) 
consisting of 15 base-pairs with each half site separated by a 6 base pair spacer 
sequence (43). Binding of QacA substrates to QacR causes the derepression of 
qacA transcription. This event leads to the overexpression of the QacA transporter 
and thus, to MDR in S. aureus. The direct interaction between QacR to structurally 
unrelated QacA substrates like benzalkonium, dequalinium, ethidium bromide, 
chlorhexidine and rhodamine 6G induces conformational changes in QacR which 
results in a reduction of its binding affinity to the IR1 operator DNA (43). 
Interestingly, plant alkaloids such as berberine, an amphipathic cationic compound, 
induces both the expression of the plasmid encoded qacA and chromosomally 
encoded norA genes, which both encoded for MDR transporters (47). Therefore, 
the QacA-QacR system provides protection against compounds produced by plants 
and naturally derived cationic and hydrophobic antimicrobial agents. The presence 
of the qacA-qacR locus on multi resistance plasmids in clinical S. aureus strain 
suggests that the system also functions to protect cells against synthetic man-made 





QacA may have evolved from QacB to provide resistance against clinical drugs 
(124). 
  DNA binding: QacR binds to the palindromic sequence at the IR1 DNA 
operator site as dimers. Upon addition of substrates, the four DNA bound QacR 
molecules dissociate as dimers (44). This observation shows that QacR does not 
self assemble into tetramers, while the two dimers appear to have no direct contact 
with each other in the DNA bound state (44). QacR adopts a somewhat different 
DNA binding mode than TetR (153). The structure of the QacR: DNA complex 
shows that the two QacR dimers bind to the extended 28 base pair IR1 operator on 
the opposite sites, in which the two HTH motifs from each dimer make a contact 
with the DNA major groove (153). QacR comprises nine α-helices (153). The first 
three helices form the three helix bundle DNA binding domain of the HTH motif 
(α2 and α3). DNA recognition occurs in the α3 helix. The DNA binding domain of 
QacR is highly homologous to TetR but the N-terminus of α1 in QacR makes 
contact with the phosphate backbone in a different orientation than the 
corresponding helix in TetR (153). The dimerization domain/substrate binding site 
of QacR comprises α-helices 4 to 9 that show a low homology to the corresponding 
domain of TetR. The C-terminal anti-parallel α-helices from each dimer form a 
four helix dimerization region (153). 
  The QacR dimers bind cooperatively to the operator DNA which is an 
exceptional feature among members of the TetR transcriptional regulators (153). 
Gel filtration and light scattering studies are consistent with a cooperative binding 
of two QacR dimers to the IR1 DNA (153). Because of the large distance of > 5 Å 
between each dimer, this cooperative binding mode does not seem to involve 
protein-protein interactions (153). Rather the structure and adopted conformational 
changes in the DNA inflicted by the bound QacR causes such a cooperative 
binding behavior (153). There are 16 bases and 44 phosphate contacts with the IR1 
site generated by the binding of the two QacR dimers. Each monomer contacts the 
DNA differently; one distal and one more proximal to the dyad, each recognizing 
particular bases (153). The removal of two base pairs from the wild-type six base 
pair spacer region abolishes the binding of QacR, confirming that spacing is 
important for proper binding to the IR1 operator. A common feature of the 
TetR/CamR members of transcriptional regulators is their short recognition helix 
that insert deeply into the floor of the DNA major groove. One notable difference 
between TetR and QacR concerns their DNA binding mechanism. Upon binding to 
the DNA, TetR induces a bending of 17° of the DNA towards the protein that 
optimizes the HTH interaction within each DNA half-site including a widening of 
the DNA major groove. On the other hand, the entire IR1 operator widens upon 





3° (153). The HTH motif of TetR makes identical contacts to each symmetry DNA 
half site which is a common feature of dimer binding to a palindromic sequence in 
protein-DNA interactions. However, each HTH motif of the QacR dimer makes 




Figure 2. The crystal structure of QacR: DNA complex solved at 2.90 Å resolution. The four 
identical monomers of QacR form two functional dimers and bind to the symmetrical version of a 28 




 Drug binding: QacR shows an unusual feature of overlapping mini pockets 
within its large hydrophobic drug binding site (151). These mini pockets can bind 
different substrates, and serves as a model for multi-site binding allowing 
interactions with a range of structurally distinct drugs. Structural studies on both 
AcrB transporter that contain such mini pockets as well as the transcriptional 
regulator QacR revealed interactions between these mini pockets and displayed no 
clear boundaries (151). Moreover, a low resolution structure of the MDR 
transporter AcrB was shown to bind four different drugs simultaneously (151). 





binds to a variety of positively charged substances, TtgR binds negatively charged 
toxins due to the presence of polar residues in its hydrophobic binding pocket. 
TtgR also bind a broad range of naturally occurring antimicrobial compounds such 
as phloretin, quercetin and naringenin (10). Interestingly, the QacR dimer always 
binds only one ligand whereas the TtgR dimer has been showed to bind up to three 
molecules of phloretin; two molecules at low- and one molecule at the high affinity 
binding sites. The multidrug binding pocket of TtgR is larger in comparison to 
QacR and posses two overlapping binding sites; a highly hydrophobic general site 
that binds compounds such as tetracycline, chloroamphenicol, quercetin, and 
naringenin (one ligand per TtgR dimer), and a polar site for high affinity phloretin 
binding pocket (10).  
 QacR exhibits positive or negative cooperativity between certain drug 
classes as well as non cooperative and uncooperative interaction with others (151). 
QacR binds both mono- and bivalent cationic drugs. Monovalent drugs like 
rhodamine 6G and ethidium bromide bind non simultaneously to different but 
overlapping regions of the extended QacR ligand binding pocket (152). Because of 
the presence of flexible carbon atom linker in the bivalent dequalinium, this 
molecule can interact with both binding sites of QacR. Rhodamine 6G and 
ethidium bromide bind through their ring system (152). Hence, it appears that 
QacR also can bind two (or more) drug simultaneously at overlapping binding 
sites.  
 Proflavin and rhodamine 6G bind QacR at overlapping sites. Upon 
binding, proflavin stacks with the side chains of Trp61 and Tyr93, whereas Glu57 
and Glu58 help to neutralize the positive charge and sandwich the proflavin ring 
system in place (151). In the QacR dimer, proflavin binds at the same site as 
rhodamine 6G and both compete for binding (151). Rhodamine 6G and ethidium 
bromide bind to different but overlapping binding sites. These drugs do not bind to 
the QacR dimer simultaneously possibly because of steric hindrance (151). The 
structure of QacR in complex with both proflavin and ethidium bromide was 
solved at 2.96 Å resolution (151). Binding of both drugs simultaneously did not 
result in additional structural changes of the QacR dimer (151). Upon dual drug 
binding to the QacR dimer, structural comparison between the QacR: proflavin: 
ethidium bromide and QacR: ethidium bromide binary complexes showed the 
ethidium bromide molecule had shifted to another pocket to avoid clashing with 
proflavin. This adjustment offers a closest ring-to-ring approach of 4.0 Å engaging 
ethidium bromide in a favorable van der Waals interaction with proflavin while 
still preserving the hydrophobic and aromatic stacking interactions with the QacR 
protein (151). Aromatic residues play a critical role in drug binding. They are 





drug-binding induced conformational transitions allowing the drug to slide into the 
binding pocket while still maintaining stacking interaction (151).  
 
Regulation of drug resistance transporters Bmr and Blt in Bacillus subtilis 
 
Bmr and Blt are two MDR transporters of B. subtilis. They shares up to 51% amino 
acids sequence homology and when overexpressed they are involved in the export 
of a similar range of drugs (4). Unlike bmr, blt is not transcribed in the wild-type 
cells. Likewise, disruption of the bmr gene but not of blt causes cells to be more 
susceptible to toxic drugs (4). Bmr is involved in the export of a diverse range of 
compounds that are lipophilic, monovalent and cationic (3,178). Most of the 
substrates are also substrates of P-gp and the transport activity of Bmr can be 
inhibited by reserpine and verapamil. Interestingly, cells challenged with 
rhodamine did not show neither the up regulation of blt transcription nor the 
interaction of this compound with the transcriptional activator BltR, whereas in 
vitro, rhodamine is a substrate for the Blt transporter (4). This suggests that the 
substrates binding domains of BmrR and BltR are functionally different.  
 DNA binding: The level of expression of bmr and blt is under a control of 
transcriptional activators BmrR and BltR, respectively (4). These proteins belong 
to the MerR family of transcriptional regulators. Although BmrR and BltR are very 
homologous in their N-terminal DNA binding domains, their C-terminus drug(s) 
binding site show little sequence homology (4). Unlike BmrR, the identity of the 
ligand(s) that bind BltR is still unclear although is it clear what substrates are 
transported by Blt. The bmr and blt genes localize in different operons. The bmr 
promoter exclusively controls the expression of bmr while the blt promoter 
controls the expression of two genes, blt and bltD. BltD is highly homologous to an 
acetyltransferase that could implicate a metabolism-associated function of the Blt 
transporter (4). 
 Transcriptional activation of both bmr and blt genes is subject for 
regulation by the global activator Mta (13). A truncate of Mta that comprises only 
the N-terminal DNA binding domain (MtaN) binds both the promoter regions of 
bmr and blt at exactly the same nucleotide sequences that are bound by BmrR and 
BltR, respectively (13). MtaN comprises the winged HTH motif that is structurally 
related to the same region of BmrR. However, the α5 dimerization helix and the 
first wing of the DNA binding domain of MtaN are in different orientations as 
compared to the corresponding regions in BmrR suggesting these two protein 
interact with DNA in a distinct manner (13). With respect to the drug binding 
domain, Mta is homologous to the global regulatory protein of multidrug resistance 





may be at the level of global control, and their expression can be effected by 
stresses induced by means of the presence of toxic compounds or peptides in the 
medium. The S. aureus NorA protein is homologous to the B. subtilis Bmr and Blt 
(4). Likewise, NorA provides resistance to the cells to a similar panel of drugs as 
transported by BmrE. However, little is known about the regulation of norA 
expression.  
 The BmrR dimer directly interacts with drugs. Ligand-bound BmrR binds 
to the inverted repeats located between the -35 and -10 region of bmr promoter 
region. The -35 and -10 consensus motifs are separated by a 19 base pair spacer 
sequence which is quite long as compared to the typically observed 16-17 base 
pairs (4). The long spacer sequence together with the location of the -35 and -10 
region on the other side of the DNA helix are necessary to prevent activation of 
bmr transcription by RNA polymerase in the absence of drugs (4). The constitutive 
drug resistance phenotype of selected B. subtilis strains is caused by a 2 base pair 
deletion in the spacer region of bmr promoter causing continuous overexpression 
of Bmr (54). Constitutive expression of blt was observed in B. subtilis 168ACF that 
carries the acfA mutation, i.e., a 1 base pair deletion in the spacer region of the blt 
promoter (4). 
 BmrR belongs to the winged-helix superfamily of a four-helix-bundle and 
a three stranded antiparallel β sheets (39). The topology of BmrR HTH motif 
corresponds to β1, α1, α2 (recognition helix), W1 (sheets β2 and β3), W2 (α3 and 
α4) with α5 function as a linker connecting the DNA and substrate binding 
domains (54). The DNA binding elements of BmrR are responsible in making 
contacts with the bmr promoter while still promoting the favorable DNA 
conformation for binding of RNA polymerase (54). The residues Ser41, Tyr42, and 
Arg43 in W1 are necessary for DNA binding through van der Waals interactions 
and hydrogen bonding. Moreover, Arg43 together with a glutamate, aspartate or 
glutamine at position 26 are conserved amongst MerR family members indicating 
that W1 is an important DNA binding element (54). In contrast to other winged-
helix proteins, α2 and α3 of W2 of BmrR are part of the HTH motif rather than 
forming a loop (54).  
 The structure of the ternary BmrR:TPP+:DNA complex shows a 
remarkable twisting of the promoter region with a reorientation of the -35 and -10 
region to allow RNA polymerase to bind and initiate transcription (54). This 
mechanism involves base pairing disruption of 2 residues in the center of the 
pseudodyad of the bmr promoter (54). The A-T base pair at +1 position breaks 
causing the adenine and thymine to slide away from each other. On the other hand, 
the A-T base pair at the -1 position is able to form miss-pairing interaction 





“bunches up” in the middle of the operator region and a space shortening 
equivalent to 2 base pairs (54). Residues Tyr24, Tyr25, Lys60, and Lys66 of BmrR 
stabilize the base pair distortion via contact with the DNA back bone (54). 
 Drug binding: The binding of ligands to BmrR was previously studied 
using the isolated C-terminal substrate binding domain (BRC) (87). This domain 
can be readily expressed, dimerized, and able to bind two drugs per dimer (87). 
This finding is consistent with the BmrR:drug:DNA complex which shows one 
drug molecule bound per BmrR monomer (54). There is no obvious binding pocket 
or cavity found in apo BRC structure (192). However, the BRC:TPP+ structure 
revealed the presence of a charged residue (Glu134) buried in the core of the 
protein but positioned at the base of the binding site (192). Ligand binding occur 
via electrostatic interaction between the negative charge of the carboxylate group 
of Glu134 with the positively charged substrates like TPP+ or Rhodamine 6G (192). 
Glu21 initiates the entry of TPP+ into the internal binding site of BRC. This residue 
is located proximal to α2 and creates a negative patch that attracts cationic 
compounds (54). Binding of molecules will take place only via the unfolding of α2 
(54). The BRC Glu134Ala mutant shows reduced binding affinity to five out of six 
BmrR ligands (178). This suggests the presence of a multi variant binding site that 
can accommodate a diverse range of chemically unrelated compounds. Structural 
comparison between the apo BRC and BRC:TPP+ showed no major 
conformational changes which suggests the unwinding of α6 in BmrR may act as a 
signal during drug induced transcriptional activation (192).  
 
Figure 3. A structural overview of the BmrR dimer with bound DNA and drug TPP. The N-
terminus is responsible for the DNA binding domain and it is directly linked to the C-terminus which 
comprised two-third of the protein responsible for the ligand binding domain indicated by a long helix 





TetR regulates the expression of the specific tetracycline MDR pump: TetA 
 
The overexpression of TetA transporter results in resistance to tetracycline. TetA 
belongs to the MFS and specifies an antiporter that mediates the extrusion of 
tetracycline in complex with a divalent metal cation e.g. Mg2+ in exchange for 
protons. Unlike Gram-positive bacteria, expression of tetA in Gram-negative 
bacteria is controlled by the product of a divergently transcribed gene, the tetR 
repressor (56). TetR proteins can be classified into 8 subfamilies, i.e., TetR A to E, 
G, H, and J (144). TetR proteins are transcriptional regulators that control the 
transcription of various genes associated with antibiotic biosynthesis, osmotic 
stress, multidrug resistance, and pathogenicity in both Gram-positive and -negative 
bacteria (135).  
 The best characterized TetR protein is encoded by the Tn10 gene. TetR(B) 
binds to the overlapping sequences of tetA(B) and two divergent tetR(B) promoter 
regions (56). Homodimeric TetR binds non-cooperatively to the two adjacent 
inverted repeats known as the tet operators O1 and O2 that overlap with the tetA(B) 
and tetR(B) operator DNA region (98). Binding of TetR in the presence of the 
tetracycline-Mg2+ complex induces conformational changes in TetR, whereupon 
derepression of both tetA and tetR genes occur which expel tetracycline from the 
cell (57). TetR shows a higher binding affinity for tetracycline-Mg2+ complexes 
than the drug target, the ribosomes. This ensures a full protection to the cells via 
TetA overexpression (56). TetR binding affinity to O2 is four folds higher than to 
the O1 sequence (69).The binding of TetR to O1 results in a complete block of 
transcription of both the tetA and tetR genes, whereas down regulation of tetA(B) 
but not tetR(B) gene is being observed when TetR binds to the O2 site only (98). 
When the low amount of repressor-operator bound complex is detected, the 
synthesis of tetR(B) but not tetA(B) is being activated. In addition, the uncontrolled 
expression of the integral membrane protein TetA is lethal to the cells as 
nonspecific cation transport causes a collapse of the Δψ (35).  
 TetR(D) is organized as a dimer. The crystal structure of the TetR(D):tetO 
complex shows that each subunit comprises of 10 α-helices (117). α8 and α10 from 
each monomer form antiparallel helices that are part of the four helix bundle of the 
dimerization domain (57,146) and protein-protein interaction (145,150). The HTH 
motif of TetR comprises α2 and α3 while α1 stabilizes the HTH structure and α4 
contributes to the formation of a hydrophobic center in the DNA binding domain 
that is critical for the binding of TetR to the tet operator (117). In addition, 
truncation at the N-terminal region of TetR abolished the binding to DNA (17). In 
the TetR(D) bound tetracycline-Mg2+ complex, both α3 and α3’ were found to be 





DNA major grooves that are about 34 Å apart (57). TetR (D) binds to the 15 base 
pair fragment of the tet operator except for the central 3 base pairs. Under those 
conditions, α3 and α3’ of the TetR dimer are separated by 36.6 Å while binding of 
the drug increases this gap by 3 Å (117). The TetR-DNA interface contains no 
water molecules unlike common protein-DNA interaction. Pro39 of the HTH motif 
plays an important role in establishing this particular contact in the TetR-DNA 
complex (53,117,180). The ligand induced conformational changes of TetR(B) and 
TetR(D) have been described in detail elsewhere (52,57,104,148,149,158). The 
TetR homodimer traps two tetracycline-Mg2+ molecules inside tunnels that are 
located in the center of the protein (57). Each of the binding tunnels consists of α-
helices that are derived from both monomers; the first tunnel comprises α-helices 4 
to 8 and 8’ and 9’ while the second one consists of α-helices 4’ to 8’ and 8 and 9. 
The structure of ligand-bound TetR shows a large opening adjacent to the C-
terminus at α9 (and α9’ from the other subunit) that was not observed with the apo 
TetR. This large opening functions as a drug entry gate (57,115). The tetracycline 
derivative glycylcycline contains a glycylamido substituent that causes steric 
hindrance thereby interfering with the TetR sliding door α9’. This ligand does not 
induce the depression of tetA (118). By means of a chelator, the Mg2+ can be 
removed from the TetR:tetracycline-Mg2+ complex, and the resulting 
TetR:tetracycline complex has almost a similar conformation as the apo TetR. This 
demonstrates that Mg2+ fulfils a critical role in the induction mechanism (116). 
Further details on the mechanism of TetR regulation can be found elsewhere 
(18,115-117,148,169-171,179). 
 
The multiple antibiotic resistance (mar) regulon in Escherichia coli  
 
E. coli is resistant to multiple compounds such as dyes, antimicrobial agents, 
detergents, fluoroquinolones, and numerous antibiotics including β-lactams, 
chloroamphenicol, erythromycin, and tetracycline. This resistance is caused by the 
overexpression of the tripartite drug efflux pump AcrAB-TolC 
(84,96,109,114,184). The physiological function of the AcrAB-TolC complex in E. 
coli is to transport stress related toxic compounds that are found in natural 
environments such as fatty acids and bile salts (84,109,168). The overexpression of 
the global regulators MarA, SoxS, and Rob modulates the expression of many of 
the mar regulon genes by binding to the marbox upstream of each promoter. The 
mar box is a 20 base pair nucleotide sequence motif located in the promoter region 
of the target genes such as the acrAB and tolC genes (6,113,182). Previous studies 





other (91,99,100,111), suggesting the presence of additional binding sites within 
the mar, sox and rob promoters.  
Mutations in AcrR, a divergently transcribed local repressor of acrAB 
operon cause the increased resistance to fluoroquinolones in clinical E. coli isolates 
(66,110,181). AcrR posses the typical HTH DNA binding motif and belongs to the 
TetR family of transcriptional regulators (83). AcrR represses both transcription of 
acrR and acrAB but it does not induce the expression of these genes under general 
stress conditions such as 4% ethanol, 0.5 M NaCl, or when cells enter the 
stationary phase (83). Transcription of these genes is linked to an unidentified 
regulatory protein (83). Thus, the expression of acrAB is primarily controlled by 
AcrR while its induction is modulated by MarA and other global regulators. 
Previous results indicate that the physiological function of AcrAB might relate to 
the export of non-freely diffusible quorum sensing molecules (134). AcrAB 
expression increases as the growth rate decreases and this might be linked to the 
accumulation of the quorum-sensing signals produced by the cells (83,136).  
MarA belongs to the AraC family of transcriptional activators 
(64,65,91,137). The cellular level of MarA is controlled by the MarR repressor, the 
first gene of the marRAB operon. Both MarA and MarR bind to the DNA region 
marO that is located upstream of the marR gene and contains several regulatory 
binding sites surrounding the marRAB promoter (45). MarA binds to the marbox of 
a large number of mar regulon genes (6), and it also activates its own transcription. 
The MarA binding site is located 16 base pairs upstream of the -35 and -10 region 
of the marRAB operon (91,137). Over 60 chromosomal genes are differentially 
regulated in E. coli cells that constitutively express marA (14). In another study 
describing the inducible MarA expression system, an additional of 67 MarA-
regulated genes were identified (128). MarA activates at least 40 different 
promoters of target genes (95), and also a gene with a marbox that diverges 
substantially from the consensus sequence (15). One example is the transcriptional 
activation of micF by MarA. This gene produces an antisense RNA that repress the 
expression of ompF, a gene codes for the outer membrane protein that allows 
passive diffusions of small molecules (34). Thus, reduced drug influx by OmpF 
combined with an active extrusion by AcrAB-TolC is a very efficient response 
mechanism controlled by MarA when cells are exposed to toxic molecules. A 
recent study also shows that MarA functions as the repressor of rob transcription in 
E. coli (147). 
MarA binds DNA as a monomeric protein. The DNA binding site lacks 
any inverted or direct repeats commonly characterized in bacterial regulatory 
sequences. Interestingly, MarA and its homolog SoxS posses no ligand binding site 





members of the AraC family (94). The crystal structure of MarA:marO complex 
reveals an unusual feature of two HTH DNA binding motif that are connected by a 
long α-helix (90). A typical HTH binding motif can recognize only 6 base pairs out 
of the 11-12 base pairs of the operator sequence (161). This is the reason why most 
of the bacterial regulatory proteins need to dimerize to comprise two HTH motifs. 
Monomeric MarA is capable of binding to two successive DNA major grooves 
utilizing its two HTH domains. A previous study revealed that the N-terminal HTH 
domain of MarA contacts the marbox consensus sequences (42). A more detailed 
description of the MarA:DNA complex and the binding mechanism can be found 
elsewhere (30,42,89,90).  
 MarR repress the transcription of the marRAB operon by binding to marO 
at sequences different from the marbox that is recognized by MarA (91). MarR 
binds as a dimer to two site in marO, assigned as site I and II located downstream 
from the MarA binding site (92). To a certain extent, MarA and MarR compete for 
binding to marO (91). Site I overlaps the -35 and -10 region while site II is neither 
required for repression nor it is needed for binding of MarR to site I (92). The 
crystal structure of MarR has been solved at 2.3 Å showing that MarR posses the 
typical DNA binding domain of the winged-helix family (9). The α3 and α4 helices 
of MarR form the HTH motif with the β-sheets functioning as the “wings”. 
Importance residues for DNA recognition by MarR are located in the α4 helix as 
mutations in this region abolish DNA binding (5). The structure of MarR is 
stabilized by a number of salt bridges (9,76). MarR binds antibiotics like 
tetracycline and chloroamphenicol, weak aromatic acids like salicylate, and other 
compounds such as the redox cycling molecules menadione and plumbagin 
(7,155). Salicylate binds to two sites on each subunit of the MarR dimer. These 
binding sites are located at the surface near to the DNA recognition helix α4 (9). 
Hence, the binding of the inducer disturbs MarR binding to marO, causing the 
depression of marRAB, and mar regulon activation via the synthesis of MarA (45). 
In addition, the MarA homologs SoxS and Rob bind to marO DNA and activate the 
expression of genes belong to the mar and sox regulon which contributed to the 
MDR phenotype of E. coli. In addition, the nucleoid-associated global regulatory 
protein known as FIS also bind to a region within marO upstream of the marbox. 
FIS stimulates the MarA, SoxS, and Rob mediated activation of transcription. 
Further information on SoxS, Rob and FIS can be found in references 
(64,65,83,93,94,101,112,114,137,138,165,172,184). Analogous mar regulatory 
networks are found in many bacterial species suggesting that these organisms carry 







PadR, a new family of transcriptional regulator involved in multidrug 
resistance  
 
LadR is a transcriptional regulator that controls the expression of the MDR 
transporter MdrL in Listeria monocytogenes (61). Overexpression of MdrL results 
in the rapid efflux of rhodamine 6G out of the cells. Interestingly, LadR belongs to 
the PadR family of transcriptional regulators, while most of the MDR specific 
transcriptional regulators belong to the MerR, AraC, or LysR family of activators 
or are members of the TetR, MarR, or LacI family of transcriptional repressors 
(46). PadR regulators are involved in regulating the expression of the phenolic acid 
decarboxylase (pad) gene(s) that detoxifies derivatives of phenolic acids such as ρ-
coumaric, ferulic, and caffeic acids (48). Some organisms such as Pseudomonas 
strains (40,119) and Acetinobacter calcoaceticus (154) use these compounds as a 
sole source of carbon for growth. Based on phylogenetic analysis of related 
firmicutes, LadR forms an independent group in a large family of PadR regulators 
(PF03551). There are two distinct families of the padR-related genes: subfamily I 
of longer sequence of about 176 amino acids, and subfamily II of shorter sequence 
of about 110 amino acids (61). LadR is the product of divergently transcribed gene 
ladR that is located upstream of mdrL, and it is conserved in all sequenced Listeria 
genomes. LadR proteins of L. monocytogenes, L. innocua, L. ivanovii, and L. grayi 
are closely related to the PadR protein of Pediococcus pentosaceus (61). The 
intergenic region of ladR-mdrL is 166 base pairs long and contains two non 
overlapping putative -35 and -10 regions (61). The -35 region of the mdrL 
promoter contains an inverted repeat with a sequence that fits with the consensus 
motif of the PadR binding site, i.e., ATGT-8N-ACAT (61). LadR is a 176 amino 
acids long protein with a low sequence identity (24-29%) with PadR regulators 
from Pediococcus pentosaceus (16) and Lactobacillus plantarum (48). The PadR 
proteins from P. pentosaceus and L. plantarum negatively regulate the padA gene 
specifies the phenolic acid decarboxylase (16,48). LadR shares 25.5% homology to 
the repressor and co-activator AphA of Vibrio cholerae (33,71,72). AphA is a 
quorum sensing regulator that activates the virulence cascade of V. cholerae and 
works in conjunction with another regulator AphB. AphA is a repressor of the 
penicillin amidase activity coded by pva gene (71,72). The crystal structure of 
dimeric AphA (33) reveals a number of conserved residues that are also found in 
LadR (61). AphA has two domains; a globular N-terminal domain and a distinct C-
terminal domain. The N-terminal domain of AphA adopts the winged-HTH motif 
similar to MarR (33). MdrL, QacA/B, and Bmr have a common ability to bind 
rhodamine 6G. A LadR-dependent regulation model for the expression of mdrL has 





at the PadR box and repress the transcription of mdrL gene. In the presence of 
rhodamine, deactivation of LadR takes place, and the transcription of mdrL gene is 
initiated resulting in the overexpression of MdrL which in turn mediates the efflux 
of rhodamine from the cells. Since LadR is a newly identified member of PadR 
family, its exact physiological functions in both non pathogenic and pathogenic 
Listeria species remains to be determined.  
 
LmrR regulates the expression of the major MDR ABC transporter LmrCD 
of Lactococcus lactis  
 
The Gram-positive bacterium Lactococcus lactis is a non-pathogenic bacterium 
and widely used in the fermented food production. The genome of L. lactis 
contains about 40 genes that encode putative MDR transporters (21,183). By 
heterologous expression in drug-sensitive E. coli strains, the MDR transporters 
LmrA and LmrP have been implicated in the drug resistance phenotype of L. lactis. 
However, recent gene inactivation analysis suggests that the intrinsic multidrug 
resistance of L. lactis is due to the expression of the ABC transporter LmrCD. 
LmrC and LmrD are half-transporters that heterodimerize to form a functional 
MDR transporter (82). Overexpression of LmrCD is sufficient to protect cells 
against several hydrophobic drugs e.g. daunomycin, ethidium bromide, Hoechst 
33342, and the fluorescence dye BCECF-AM (82). Moreover, LmrCD was 
recently being shown to transport bile acids as one of its natural substrates (190). 
Deletion of lmrCD in L. lactis NZ9000 renders the cells to be hyper sensitive to 
drugs such as Hoechst 33342, daunomycin, ethidium bromide, rhodamine 6G, and 
cholate. The drug resistant phenotype can be restored by the expression of lmrCD 
but not lmrA (81). Transcriptome analysis of four drug resistant strains of L. lactis 
adapted to increasing concentration of daunomycin, ethidium bromide, cholate and 
rhodamine 6G (20) revealed a similar response of the up regulation of lmrC and 
lmrD, and another gene termed lmrR (formerly ydaF) (81). The lmrR gene 
(lactococcal multidrug resistance regulator) is located upstream of the lmrCD 
genes. Nucleotide sequencing on lmrR in the four MDR strains showed frame shift 
and point mutations resulting in the production of non functional LmrR variants. 
The up regulation of lmrR in these MDR strains suggested an autoregulation 
mechanism of lmrR expression. Moreover, the constitutive expression of lmrC, 
lmrD, and lmrR in the MDR strains indicates that LmrR functions as transcriptional 
repressor for both lmrCD and for its own transcriptions. Transcriptome analysis of 
the ΔlmrR strain showed only the up regulation of the lmrC and lmrD genes, 
implying that LmrR is a specific local transcriptional regulator of the expression of 





are about 29 base-pairs apart. This separation is longer compared with the other 
known bacterial repressor DNA binding sites e.g.  MarR, a 13 base-pairs separation 
(92). The lmrCD promoter contains two sites for LmrR binding, i.e., site I is 
located between the -35 and -10 region, whereas site II consists of short imperfect 
palindrome sequences. Interestingly, in vitro site II is not essential for LmrR 
binding.  
Based on homology, LmrR belongs to the PadR family of transcriptional 
regulators (Pfam PF03551). The palindromic motif of ATGT-8N-ACAT is 
conserved among the PadR-like regulators, and LmrR binds to a slightly modified 
but highly homologous motif, i.e. ATGT-10N-ACAT. LmrR also bind to a long 
stretch of DNA on its own promoter region with no apparent structural features. 
Interestingly, many of the PadR regulators are involved in the detoxification and 
enzymatic degradation of phenolic acid, whereas LmrR regulates the expression of 
an MDR transporter that expels toxic molecules from the cell.  
LmrR, like other PadR regulators shares the typical winged-helix turn helix 
motif in its N-terminal DNA-binding while the C-terminal domain specifies the 
substrate recognition. LmrR of L. lactis and PadR-related proteins of 
Staphylococcus, Enterococcus, and Streptococcus belong to the subfamily I of 
PadR protein that are smaller (~110 amino acids long) than the subfamily II 
proteins to which PadR of L. lactis belongs (~ 176 amino acids long) (61). 
Sequence alignment of LmrR with the members of the PadR (and the more 
distantly MarR family) indicates the presence of highly conserved amino acyl 
residues that are located in the hinge region which connects the DNA- and 
substrate binding domains (9,85), that are critical for DNA binding ability. 
The crystal structures of apo LmrR, LmrR bound Hoechst 33342, and 
LmrR bound daunomycin were solved at 2.0 Å and 2.2 Å, respectively (85). LmrR 
follows α1-α2-α3-β1-β2-α4 topology with two defined domains. The first domain 
of the typical winged-helix turn helix DNA binding consists of helices α1, α2, and 
the DNA recognition helix α3 together with strands β1 and β2 to form the wing. 
The LmrR protein derived from the rhodamine challenged MDR strain is non 
functional due to a point mutation of a highly conserved threonine located in the 
hinge (wing) region of β2. This mutant is unable to bind to the promoter regions of 
both lmrCD and lmrR and hence, constitutive transcriptions of these genes take 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4. The crystal structure of apo LmrR was solved at 2.0 Å resolution. The N-terminal 
domain of LmrR is responsible for DNA binding and adopts a winged-HTH motif. The unique 
architecture of LmrR is marked by the presence of a symmetric central pore formed by the C-terminal 




 The substrate binding domain of LmrR is made up of a long α4 
dimerization helix. The dimerization helix of α4 resembles a protruding arm that 
intersects with the wHTH domain of the dyad-related subunit with the anti parallel 
orientation against α1’ and interacting with the C-terminal region of α2’, and the 
loop connecting helix α2’ and α3’. Interestingly, neither the C-terminal helices of 
α4 and α4’ nor the N-terminal of α1 and α1’ interact with each other. A striking 
structural feature of LmrR is the presence of a large flat-shape central pore for 
ligand(s) binding. This organization is unique because none of the MarR/PadR 
related transcriptional regulators possess a central pore at their dimer interface. 
Moreover, both drug binding sites of BmrR from B. subtilis and QacR from S. 
aureus are asymmetric that formed within a single subunit whereas LmrR posses a 
symmetric binding pocket where both subunits contribute equally to this structure 
(85). Hoechst 33342 and daunomycin show a common mode of binding: their flat 
ring systems are wedged in between the W96 and W96’ side chains forming 
aromatic stacking interactions with each of the two indole systems with no 
hydrogen bonds were observed between drug(s) and LmrR. 
 A difference in LmrR binding mechanism to the lmrCD promoter and its 
own promoter was demonstrated by Atomic Force Microscopy (AFM) analysis. 
With a DNA fragment corresponding to the lmrR promoter, a severe deformation 
and supercoiling of the DNA strands occurred upon LmrR binding. This likely to 
ensures a tight repression of lmrR transcription. On the other hand, the binding of 





of two “blobs.” This data suggest the transcription initation by RNA polymerase is 





 The emergence of the resistant pathogenic bacterial strains towards a wide 
range of antibiotics from different classes is progressing in an alarming speed 
causing a serious threat to public health worldwide. This phenomenon is based on 
selection for organisms that gained the ability to survive the lethal doses of 
antibiotics over time. For examples are the Mycobacterium tuberculosis (XDR-
TB), Methicillin-resistant Staphylococcus aureus (MRSA), and Vancomycin-
resistant Enterococcus (VRE) strains that are highly resistant to different classes of 
antibiotics available nowadays (1,159). The observed antibiotic resistance in 
bacteria can be either intrinsic or acquired. Intrinsic resistance is based on the 
natural mechanisms present in these cells and dependent on the genetic content of 
the cell. Acquired resistance may relate to different mechanisms such as the 
occurrence of mutations in the transporter and/or regulatory genes that changed 
expression and/or selectivity of the MDR transporters, or was obtained by 
horizontal transfer of the mobile genetic elements that carry genes encoded for 
resistance to antibiotics (132). Bacteria do not posses specific defense mechanisms 
to extrude the synthetically introduced antibiotics. Active secretion of drug 
molecules from the cell results in a multidrug resistance (MDR) phenotype that is 
often reinforced by the (over)expression of membrane bound MDR transporters. 
Sequence analysis of a number of bacterial genomes revealed that these 
transporters appear ubiquitous in nature. One of the known physiological functions 
of the MDR pumps is to provide an extensive protection against a diverse range of 
toxic molecules found in their natural environment. The employment and 
modification of these existing transport systems is subject to regulation by 
transcriptional regulators that ensure expression of the membrane transporter only 
when needed in response to the environmental stimuli. Possibly, an excessive 
production of these proteins is lethal or disadvantageous to the cells. 
The study of the mechanism of drug extrusion and recognition by MDR 
transports is hampered by the difficulty to obtain structural information as these 
membrane proteins often resist crystallization. On the other hand, the MDR related 
regulatory proteins are soluble, relatively easy to over express and often can 
successfully be transformed in high diffracting crystals. These proteins have been 
showed to contain multiple ligands binding sites that recognized the drugs that are 





they can provide detailed information on the mechanisms of multiple drug 
recognition. The next stage of analysis is to understand how these drugs affect the 
ability of these regulators to interact with DNA and how this promotes expression 
of the designated MDR transporters. Molecular mechanisms causing antibiotic 
resistance are diverse and often unique for the organism under study. Therefore, a 
complete, understanding of the mechanisms of regulation and expression of MDR 
transporter may full future design of novel inhibitors that prevent such resistance 
mechanisms and thereby increase the life span of currently used antibiotics. 
 
 
SCOPE OF THE THESIS 
 
The aim of this thesis is to elucidate the molecular basis by which the 
transcriptional regulator LmrR regulates the expression of the major multidrug 
resistance ATP-binding cassette transporter LmrCD of Lactococcus lactis. Chapter 
1 provides an introduction in multidrug resistance transporter and describes the 
various regulatory mechanism involved in bacterial MDR. Chapter 2 describes the 
functional and transcriptomic study that identifies LmrCD, a heterodimeric ATP-
binding cassette transporter, as the major determinant for both intrinsic and 
acquired MDR phenotype in L. lactis. Cells lacking lmrCD genes are hyper 
sensitive to the presence of several hydrophobic drugs such as Hoechst 33342, 
daunomycin and ethidium bromide. Conversantly, the overexpression of LmrCD 
resulted in increased resistances of the cells against the toxic effects of these 
compounds. Transcriptome analysis on four drug resistance mutant strains of L. 
lactis obtained after a challenge with increasing concentration of daunomycin, 
ethidium bromide, rhodamine, and cholate revealed the up regulation of lmrC and 
lmrD genes. In addition, a common response of these cells is the up regulation of a 
gene located upstream of lmrCD termed lmrR (formerly ydaF). Sequence analysis 
suggests that LmrR belongs to the PadR family of transcriptional regulators. A 
function of LmrR as a transcriptional regulator was confirmed experimentally by 
its ability to bind to the promoter region of lmrCD. The drug resistant phenotype of 
the selected strains was caused by the constitutive up regulation of lmrCD via the 
premature termination of the lmrR gene (Chapter 2) or the expression of a non-
functional mutant of LmrR. Chapter 3 describes a further characterization of LmrR. 
Inactivation of the lmrR gene results in a constitutively high expression of the 
lmrCD genes, and does not affect the expression of other genes in L. lactis 
demonstrating that its functions as repressor of lmrCD expression only. LmrR 
binds to its own promoter and to the promoter region of lmrCD in two distinct 





mechanism in which drug binding to LmrR causes the derepression of lmrCD. 
Chapter 4 describes a primer extension analysis showing the presence of multiple 
transcripts for the lmrCD genes and only a single transcript for lmrR. Atomic Force 
Microscopy (AFM) analysis further confirmed major differences in the LmrR 
binding mode for the lmrR and lmrCD promoter regions. The binding of LmrR to 
its own promoter results in a severe DNA deformation and super coiling whereas 
binding of LmrR to the promoter region of lmrCD only causes a distinct DNA 
bending. Chapter 5 describes a structural analysis of LmrR. The crystal structure of 
apo LmrR and LmrR bound to either Hoechst 33342 or daunomycin was solved to 
atomic resolution. The N-terminal domain of LmrR comprises the typical DNA 
binding winged-helix turn helix motif as found in previously characterized 
bacterial transcriptional regulators. The LmrR structure also show some unusual 
features. The two C-terminal regions of the LmrR dimer form a flat-shape 
hydrophobic central pore that is responsible for drug binding. Hoechst 33342 or 
daunomycin bind in a similar fashion with their aromatic rings sandwiched in 
between the indole groups of two dimer-related tryptophan residues. Further 
functional analysis of site-directed mutants of LmrR suggest an allosteric coupling 
between the multidrug and DNA binding sites of LmrR that likely plays a role in 
the induction mechanism. Finally, Chapter 6 summarizes the findings of this thesis 
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